Columbia University

Technology Ventures

Latest News

APEIRON Biologics AG announced today that it has entered into an exclusive license agreement with Columbia University through their technology transfer office, Columbia Technology Ventures.
Mutations in more than 20 genes are known to cause amyotrophic lateral sclerosis (ALS), or Lou Gehrig’s disease, but much of what we know about the disease has been learned from mouse models with mutations in just one gene, SOD1, the first gene linked to ALS.
Computer Science Professor Steven Bellovin has been appointed the first Technology Scholar by the Privacy and Civil Liberties Oversight Board (PCLOB).
Three Columbia astrophysicists are celebrating a major scientific discovery – the detection of gravitational waves.
Prof. Chris Wiggins was chosen to represent Columbia University on the Business-Higher Education Forum's Data Science & Analytics Working Group.
Columbia has world-class research and industry-leading business leaders—and a new class at the Engineering School looks to bring them even closer together.
Read CTV Executive Director Orin Herskowitz's letter from our February 2016 newsletter.
The second edition of Applied Physics Professor Irving Herman’s book, Physics of the Human Body, was recently published by Springer.
A comprehensive analysis of the molecular characteristics of gliomas—the most common malignant brain tumor—explains why some patients diagnosed with slow-growing (low-grade) tumors quickly succumb to the disease while others with more aggressive (high-grade) tumors survive for many years.
Columbia University Medical Center (CUMC) and University of Iowa scientists have used a new gene-editing technology called CRISPR to repair a genetic mutation responsible for retinitis pigmentosa (RP), an inherited condition that causes the retina to degrade and leads to blindness in at least 1.5 million cases worldwide.